[º¸°ÇŸÀÓÁî] °¡Å縯´ë ¿©Àǵµ¼º¸ðº´¿ø ³»ºÐºñ³»°ú ¿¬±¸ÆÀ ³í¹®ÀÌ ÃÖ±Ù »ý¹°Çבּ¸Á¤º¸¼¾ÅÍ(BRIC, Biological Research Information Center)ÀÇ 'Çѱ¹À» ºû³»´Â »ç¶÷µé(ÇѺû»ç)' ³í¹®¿¡ ¼±Á¤µÆ´Ù.
³í¹® Á¦¸ñÀº 'Á¦ 2Çü ´ç´¢º´ ȯÀÚ¿¡¼ SGLT-2 ¾ïÁ¦Á¦ »ç¿ë°ú ¸Á¸·Á¤¸ÆÆó¼âÀÇ À§Çèµµ (Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study,
³í¹®º¸±â)'´Ù.
ÀÌ ³í¹®ÀÇ °øµ¿ ±³½ÅÀúÀÚ´Â ¿©Àǵµ¼º¸ðº´¿ø ³»ºÐºñ³»°ú ±ÇÇõ»ó ±³¼ö(»çÁø ÁÂ), ¾È°ú ³ë¿µÁ¤ ±³¼ö(»çÁø éÓ)(Á¦ 1ÀúÀÚ ÇѾç´ë ¸íÁöº´¿ø ³»ºÐºñ³»°ú ÀÌ¹Î°æ ±³¼ö)´Ù.
¹Ì±¹ ´ç´¢º´ÇÐȸ(ADA) °ø½Ä Àú³Î '´ç´¢°ü¸®(diabetes care)'´Â Àο뵵(IF, Impact Factor)°¡ 2020³â ±âÁØ 19.112·Î ³»ºÐºñ ºÐ¾ß¿¡¼ Àú¸íÇÑ ÇÐȸÁö´Ù.
ÀÌµé ±³¼öÀÇ ³í¹®Àº ÀÌ ÇÐȸÁö¿¡ 9¿ù SGLT-2 ¾ïÁ¦Á¦ Åõ¾à ȯÀÚ¿¡¼ ¸Á¸·Á¤¸ÆÆó¼â (Retinal Vein Occlusion, RVO) À§ÇèÀÌ ´õ ³ô´Ù¶õ ÁÖÁ¦·Î °ÔÀçµÆ´Ù.
¿¬±¸´Â ±¹¹Î°Ç°º¸Çè°ø´ÜÀÇ ÀڷḦ ÅëÇØ 2014³âºÎÅÍ 2017³â±îÁö Àü±¹¿¡¼ »õ·Ó°Ô Ç÷´ç°ÇÏÁ¦¸¦ ó¹æ¹ÞÀº ȯÀÚ Áß ¼ºÇâ ¸ÅĪ(Propensity Score Match, PSM)À» ÅëÇØ SGLT-2 ¾ïÁ¦Á¦¸¦ Åõ¾àÇÑ 4¸¸ 7369¸í°ú ´Ù¸¥ Ç÷´ç°ÇÏÁ¦¸¦ º¹¿ëÇÑ 4¸¸ 7369¸íÀÇ È¯ÀÚ¿¡¼ ¸Á¸·Á¤¸ÆÆó¼â ¹ß»ý À§ÇèÀ» ºñ±³, ºÐ¼®ÇÑ °ÍÀÌ´Ù.
2.57³â°£ ÃßÀû °üÂûÇÑ ¿¬±¸ °á°ú, SGLT-2¸¦ º¹¿ëÇÑ È¯ÀÚ¿¡°Ô¼ ¸Á¸·Á¤¸ÆÆó¼â ¹ßº´·üÀÌ 1000 ¸í ȯÀÚ ³â´ç 2.19¸í, ´Ù¸¥ Ç÷´ç °ÇÏÁ¦¸¦ º¹¿ëÇÑ È¯ÀÚ´Â 1.79¸íÀ¸·Î, SGLT-2 ¾ïÁ¦Á¦ º¹¿ë ȯÀÚ¿¡¼ À§ÇèÀÌ ´õ ³ô¾Ò´Ù.(HR=1.264)
ÇÏÀ§ ºÐ¼®¿¡¼± SGLT-2 ¾ïÁ¦Á¦ º¹¿ë ȯÀÚ Áß 60¼¼ ÀÌ»óÀ̰ųª ½Å»ç±¸Ã¼¿©°úÀ²(estimated Glomerular Filtration Rate, eGFR) 60mL/min/1.73§³ ¹Ì¸¸ ȯÀÚ°¡ ´õ À§ÇèÀÌ ³ôÀº °ÍÀ¸·Î ³ªÅ¸³µ´Ù.
ÇѺû»ç´Â »ý¸í°úÇÐ ºÐ¾ßÀÇ ÇмúÁö °¡¿îµ¥ IF 10ÀÌ»óÀÇ ÇмúÁö¿¡ ³í¹®À» °ÔÀçÇÑ Çѱ¹ÀÎ °úÇÐÀÚ¸¦ ¼Ò°³ÇØ¿À°í ÀÖ´Ù.
³ë¿µÁ¤ ±³¼ö´Â "Á¦2Çü ´ç´¢º´ ȯÀÚ¸¦ ´ë»óÀ¸·Î ´ç´¢º´ Ä¡·áÁ¦¿Í ¸Á¸·Áß½ÉÁ¤¸ÆÆó¼â ¿¬°ü¼ºÀ» ºòµ¥ÀÌÅÍ ºÐ¼®À» ÅëÇØ SGLT2 ¾ïÁ¦Á¦ Ä¡·á ½Ã Å»¼ö·Î ¹ß»ýÇÑ Ç÷¾×ÀÇ Á¡µµ°¡ »ó½ÂÇÏÁö ¾Êµµ·Ï ¸¸¼º ½ÅÁúȯÀ» µ¿¹ÝÇÑ 60¼¼ÀÌ»óÀÇ °í·ÉȯÀÚ¿¡ Á» ´õ ÁÖÀǸ¦ ±â¿ïÀÏ ÇÊ¿ä°¡ ÀÖ´Ù"°í ¹àÇû´Ù.
±ÇÇõ»ó ±³¼ö´Â "¸Á¸·Á᫐ Á¤¸ÆÆó¼â¿Í °°ÀÌ ÈçÇÏÁö ¾ÊÀº ÁúȯÀº ¹«ÀÛÀ§´ëÁ¶¿¬±¸¸¦ ´ë±Ô¸ð·Î ½ÃÇàÇÏ´õ¶óµµ È®ÀÎÇϱ⠾î·Á¿ö ºòµ¥ÀÌÅͱâ¹ÝÀÇ ¿¬±¸°á°ú°¡ Áß¿äÇÑ Àǹ̸¦ °¡Áú ¼ö ÀÖ´Ù"¸é¼ "´Ù¸¸ SGLT-2 ¾ïÁ¦Á¦°¡ ½ÉÀ庸ȣ, ½ÅÀ庸ȣȿ°ú¿Í »ç¸Á·ü °¨¼Ò µî ÀåÁ¡ÀÌ Å« ¾àÁ¦ÀÎ ¸¸Å ÇâÈÄ Ãß°¡ ¿¬±¸ µîÀ» ÅëÇØ Á¤È®ÇÑ Çö»ó°ú ±âÀü¿¡ ´ëÇØ Á¢±ÙÇÏ´Â °ÍÀÌ ÇÊ¿äÇÏ´Ù"°í ¸»Çß´Ù.